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Alternative splicing is involved in functional regulation of the mutagenic enzyme activation-
induced cytidine deaminase (AID). However, the molecular basis for AID splicing regulation remains
undeﬁned. Using a mini-gene-based screen in HeLa cells, we found that overexpression of RNA bind-
ing motif protein 5 (RBM5, or LUCA-15/H37) signiﬁcantly promoted AID exon 4 skipping by suppress-
ing the splicing of intron 3. The inhibitive effect of RBM5 on intron 3 splicing required a weak
30-splice site (ss). Indicative of the underlying mechanism, RBM5 interfered with the binding of
U2AF65 to the polypyrimidine tract at the 30-ss in vitro. Our ﬁndings thus not only shed lights on
the regulatory mechanism of AID exon 4 skipping, but also provide new insights into how RBM5
functions in splicing regulation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Activation-induced cytidine deaminase (AID) is essential to the
generation of human immunoglobulin (Ig) diversiﬁcation in two
different processes, somatic hypermutation (SHM) and class switch
recombination (CSR) [1,2]. AID is believed to induce DNA double-
strand breaks (DSBs) in both Ig and non-Ig genes [3,4]. Deregulated
expression of AID has indeed been reported to account for the
accumulation of oncogenic mutations and chromosome transloca-
tions in various B-cell lymphomas [5,6].
Alternative splicing is a process occurred in nearly 95% of
human multi-exon genes, by which diverse mRNA variants are
generated from a single gene [7]. Several recent studies have
indicated that alternative splicing is involved in functional regula-
tion of AID by generating mRNA variants that encode proteins con-
taining different domains [8–10]. For example, exclusion of exon 4
results in expressing a carboxyl-terminal truncated isoform of AID
with hyperactivity in somatic hypermutation [9–11]. Interestingly,
one study shows that AID splice variants are singly expressed at
individual cell level [10], indicating that splicing regulation plays
critical roles in modulating the activity of AID. However, the
molecular basis for AID alternative splicing regulation still remains
unclear.chemical Societies. Published by EPre-mRNA splicing is started from the recognition of the 50-ss by
U1 snRNP and the binding of U2AF65/35 heterodimer to the 30-ss
[12,13]. Association of protein factors to pre-mRNAs that facilitates
or impairs the binding of U1 snRNP and/or U2AF to the splice sites
is a major mechanism of alternative splicing regulation [12,14]. In
addition, decision of splice sites selection can also be inﬂuenced by
dynamic rearrangements involving both RNAs and proteins during
spliceosome assembly [15], and even affected by elongation rates
of transcription [16].
In this study, we found that overexpression of RNA binding
motif protein 5 (RBM5) stimulated exon 4 skipping in a human
AID mini-gene. We further showed that the effect of RBM5 most
likely resulted from a direct competition with U2AF65 for binding
to the polypyrimidine tract at the 30-ss of AID intron 3. Our ﬁndings
provide insights into the molecular basis of AID splicing regulation,
and also extend our understanding on the regulatory roles of RBM5
in alternative splicing.
2. Materials and methods
2.1. Cell culture and transfection
HeLa and HEK293 cells were grown in Dulbecco0s Modiﬁcation
of Eagle0s Medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (FBS) at 37 C in presence of 5% CO2. Cell transfection
was performed using Lipofectamine 2000 transfection reagents
according to the manufacturer0s instructions (Invitrogen, USA).lsevier B.V. All rights reserved.
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For AID mini-gene construct, a 1.4 kb genomic DNA fragment,
spanning from exon 3 to a portion of exon 5 of human AID gene,
was ampliﬁed from HeLa cells and inserted into HindIII/BamHI
sites of pcDNA3 vector (Invitrogen, USA). For point mutations, we
followed a PCR-driven overlap extension (OE-PCR) strategy [17].
Full-length cDNAs of human PTBP1, RBM5, RBM6, RBM10, ROD1,
SPF45, SRP20, hnRNPA1, and RNPS1 genes were ampliﬁed from HeLa
cDNA library using Pfu Turbo DNA Polymerase (Stratagene, USA),
and inserted into EcoRI/XhoI sites of the pcDNA3-ﬂag vector.
RBM5 expression construct with Glutathione-S-transferase (GST)
and histidine dual tags was obtained by subcloning of RBM5 cDNA
into the pGEX-6P-1 vector (GE Healthcare).
2.3. RNA puriﬁcation and reverse transcription polymerase chain
reaction (RT-PCR)
Cells were harvested at 24 h post-transfection. Total RNAs were
extracted using RNAiso plus (TaKaRa, Japan) according to the
manufacturer0s instructions. 2 lg of total RNAs were used for the
ﬁrst-strand cDNA synthesis by using reverse transcriptase M-MLV
(Invitrogen, USA) and oligo(dT)16. 1/10 of the synthesized cDNAs
were used as templates in PCR reaction with following conditions:
94 C, 3 min, followed by 30 cycles of 30 s at 94 C, 30 s at 58 C and
30s at 72 C. Ampliﬁed DNAs were analyzed on 2% agarose gel. The
images were captured and analyzed on Alpha-Imager system (Al-
pha-Innotech, USA).Fig. 1. Identiﬁcation of splicing factor(s) promoting AID exon 4 skipping. (A) Alternative
of AID mini-gene. Boxes represent exons, and lines represent introns. Lengths of exons a
mini-gene. FL: full-length spliced product;4E4: splice variant lacking exon 4;4E4a: spli
Detection of splice variants from AID mini-gene by RT-PCR in HeLa and HEK293 cells. (
skipping. (D) Overexpression of RBM5 induces exon 4 skipping in a dose-dependent man
700 ng of RBM5 expression construct.2.4. Puriﬁcation of recombinant protein from Escherichia coli
Expression constructs were transformed into E. coli BL21 (DE3)
strain. Cells were grown in the presence of 0.05 mM isopropyl
b-D-1-thiogalactopyranoside (IPTG) for 24 h at 10 C. Recombinant
proteins were puriﬁed as described [18].
2.5. Electrophoretic mobility shift assay (EMSA)
EMSA experiments were performed essentially as described
[19]. In brief, RNA probes were synthesized by in vitro transcrip-
tion reactions using T7 RNA polymerase in the presence or absence
of [c-32P]-UTP. The radiolabeled RNA probes (1  105 cpm) were
incubated with 0.2 pmol of recombinant RBM5 or GST control pro-
teins in a 10 ll reaction. RNA–protein complexes were separated
by 6% native PAGE followed by autoradiography.
3. Results
3.1. Overexpression of RBM5 promotes AID exon 4 skipping
To understand the regulatory mechanisms underlying alterna-
tive splicing event involving AID exon 4, we constructed a CMV
promoter-driven AID mini-gene, spanning its genomic sequence
between exon 3 and 5 (Fig. 1A, top panel). Twenty four hours after
transient transfection, three alternatively spliced variants from the
transcripts of mini-gene were detected in both HeLa and HEK293splicing pattern of transcripts from AID mini-gene. Upper panel: schematic diagram
re indicated. Lower panel: schematic diagram of alternative splicing patterns of AID
ce variant lacking the ﬁrst 30 bp of exon 4. Stop codon is indicated by a circled S. (B)
C) Strategy of a candidate based screen for splicing regulator(s) promoting exon 4
ner. For 105 cells, 100 ng AID mini-gene was co-transfected with 0, 100, 300, 500 or
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from the endogenous AID pre-mRNA in human B cells [8–10].
We next set out to establish a candidate-based screen for
potential splicing regulators that could promote exon 4 skipping in
AID mini-gene (Fig. 1C). HeLa cells were co-transfected with AID
mini-gene and individual splicing factor expression construct
(PTBP1, RBM5, RBM6, RBM10, ROD1, SPF45, SRP20, hnRNPA1, and
RNPS1). At 24 h after transfection, splice variants were monitored
by RT-PCR. Among nine candidates, we found that overexpression
of RBM5 markedly promoted exon 4 skipping of AID pre-mRNA in
a dose-dependent manner (Fig. 1D).
3.2. RBM5 suppresses splicing of AID intron 3, but not intron 4
To gain more insight into the molecular basis for the effect of
RBM5 on exon 4 skipping, we analyzed the splice variants of AID
mini-gene by RT-PCR with primers speciﬁc for individual introns
ﬂanking exon 4 (Fig. 2A, upper panel). Consistent with its stimula-
tive effect on exon 4 exclusion, overexpression of RBM5 resulted in
a sharp increase on the retention of intron 3. However, no detectable
effect on the splicing of intron 4 was observed upon RBM5 overex-Fig. 2. A weak U2AF35 binding site is required for the suppressive effect of RBM5 on the s
Locations of PCR primers are indicated in the upper panel. Alternative splicing events ac
between U1 snRNA and the 50-ss of intron 3 has no effect on RBM5-mediated exon 4 sk
snRNA base-pairing potential are shown in the upper panel. Exonic and intronic regions a
by RT-PCR (lower panel). (C) A weak U2AF35 binding site at 30-ss is required for suppressi
ss of intron 3 (upper panel). Alternative splicing events were monitored by RT-PCR (low
RBM5 overexpression on AID exon 4 skipping is quantiﬁed by the amount of exon 4 skipp
the RNA containing exon3/4/5 (lower right panel). Error bars represent standard deviatipression (Fig. 2A, lower panel). These data indicate that RBM5
promotes exon 4 skipping by suppressing the splicing of intron 3,
but not intron 4.3.3. A weak 30-ss is required for RBM5-stimulated exon 4 skipping
We next analyzed the inﬂuence of splice site strength on
RBM5-stimulated exon 4 skipping. Mutagenesis was ﬁrst intro-
duced at the 50-ss to improve the base-pairing between 50-ss and
U1 snRNA (Fig. 2B, upper panel). Our data showed that strengthen-
ing the 50-ss did not affect the activity of RBM5 (Fig. 2B, lower panel).
In contrast, a point mutation from an adenine to a pyrimidine (U/C)
at -3 position or amutation from an adenine to a guanine at +1 posi-
tion of the30-ss sharply compromised the stimulative effect of RBM5
onexon4 skipping (Fig. 2C, lane 3–8). These effectswere speciﬁc as a
point mutation from adenine to guanine at -3 position had no effect
on RBM5 function (Fig. 2C, lane 9 and10). Notably, all mutants
except for the last one generate strong binding sites for U2AF35 at
the 30-ss of intron 3 [20], indicating that a weak 30-ss in intron 3 is
required for RBM5-stimulated exon 4 skipping.plicing of AID intron 3. (A) RBM5 suppresses splicing of AID intron 3, but not intron 4.
ross the indicated introns were analyzed by RT-PCR. (B) Increase of the base pairing
ipping. Sequences of 50-ss in wild type (WT) and mutant mini-genes with their U1
re indicated in uppercase and lowercase, respectively. Splice variants were analyzed
ve effect of RBM5 on intron 3 splicing. Point mutations are introduced around the 30-
er panel). Representative RT-PCR results are presented in lower left panel. Effect of
ed splice variant, which was normalized among samples by comparison with that of
ons from at least three independent experiments.
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RBM5 protein contains two putative RNA recognition motifs
(RRMs) [21]. We next asked whether RBM5 regulates exon 4 exclu-
sion by interaction with AID pre-mRNA. The RT-PCR results showed
thatmutagenesis at the conserved phenylalanine (F) residues to ala-
nine (A) within the two RRMs signiﬁcantly compromised the func-
tion of RBM5. Moreover, the N-terminal truncation mutant lacking
of both RRMs entirely blocked the effect of RBM5 (Fig 3A and B).
To further conﬁrm that RBM5 directly binds to AID pre-mRNA,
we performed in vitro EMSA with recombinant RBM5 protein and
individual radiolabeled RNA probe covering either entire mini-gene
(p1), individual introns (p2 and p3) or exon 4 (p4) (Fig. 3C and D).
Our data showed that RNA probes p1, p2 and p3 (at a less degree),
but not p4, directly interacted with RBM5 (Fig. 3E). The interaction
between RBM5 and AID pre-mRNA was further validated by EMSAFig. 3. RBM5 directly interacts with intron 3 of AID pre-mRNA in vitro. (A) Mutations of R
of the RBM5 mutants were detected by western blotting in transiently transfected HeLa
exon 4 skipping. Representative RT-PCR result is shown in the upper panel, and quantiﬁc
on AID exon 4 skipping are quantiﬁed as described in Fig. 2. Error bars represent standar
RNA probes used in EMSA. (D) Coomassie blue staining of recombinant RBM5 protein pu
The radiolabeled RNA transcripts were incubated with puriﬁed RBM5 protein (R), GST
separated by native gel electrophoresis followed by autoradiography (lanes 1–12). (F) Com
presence of excessive amounts (10X) of non-radiolabeled RNA transcripts as competitors.
indicated by arrows and asterisks, respectively.in the presence of excessive amounts (20) of unlabeled RNA
probes as competitors (Fig. 3F). Notably, unlabeled p2 RNA probe
competed with radiolabelled p1 probe in complex formation with
RBM5 in the most efﬁcient manner.
3.5. RBM5 competes with U2AF65 for binding to the polypyrimidine
tract at the 30-ss of AID intron 3 in vitro
Our data showed that overexpression of RBM5 suppressed
splicing of AID intron 3, but not intron 4. We therefore decided
to further characterize the role of the interaction between RBM5
and intron 3 in AID splicing. We found that shortening of intron
3 to an 80-nt region (p5) immediately upstream of exon 4 did
not signiﬁcantly affect the interaction between RBM5 and RNA
(Fig. 4A and B). It has been demonstrated that RBM5 interacts with
an intronic U/C-rich sequence in caspase-2 pre-mRNA [19]. ToBM5. Domain architecture of RBM5 and mutations (upper panel). Expression levels
cells (lower panel). (B) Mutations in RRMs compromised the effect of RBM5 on AID
ations are shown in the lower panel. The effects of overexpression of RBM5 mutants
d deviations from at least three independent experiments. (C) Schematic diagram of
riﬁed from E. coli. (E) Detection of RBM5-binding region in AID pre-mRNA by EMSA.
control protein (G) or buffer (), respectively. The RNA–protein complexes were
petition EMSA. RBM5 protein was incubated with radiolabeled RNA probe p1 in the
EMSA was performed as described in (E). RBM5–RNA complexes and free probes are
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by using unlabeled RNA probes carrying either the wild type (p5)
or U/C to G/A mutations at three different regions (m1–m3) within
the 80-nt RBM5 binding sequence (Fig. 4A). Our data showed that,
compared to m1 and m2 RNAs, U to G mutations in m3 markedly
impaired its capacity in competing with wild type p5 RNA in RBM5
binding (Fig. 4B, lane 6). These data indicate that the U-rich
element, mutated in m3, is critical for RBM5 binding although
we would certainly not rule out the possibility that additional
nucleotides might also be involved in RBM5 binding.
Notably, mutated U-rich element in m3 is overlapped with the
polypyrimidine tract of intron 3. Binding of U2AF65 to the polypy-
rimidine tract is indispensible for 30-ss deﬁnition [7]. By using
EMSA, we showed that both RBM5 and GST-U2AF65 (Fig. 4C, laneFig. 4. RBM5 competes with U2AF65 for binding to the polypyrimidine tract. (A) Sequen
position of the 30-ss are indicated. (B) Competition EMSA was performed in the presenc
unlabeled wild type (p5) or mutated (m1, m2 and m3) RNA probes as competitors. The
deﬁnition of competition index (CI) is depicted. (C) RBM5 prevents the interaction of U2
(lane 2), GST (lane 7) alone or with 2 pmol of GST-U2AF65 in the presence of 0, 0.1, 0.2, o
(lane 8). Positions of RNA–protein complexes and free-labeled p5 RNA are indicated by a
exon 4 skipping. Recruitment of U2AF65/35 heterodimer to the polypyrimidine tract and
the binding of U2 snRNP at the branch point during prespliceosome assembly. RBM5 co
attenuates the association between U2AF35 and a weak binding site at the 30-ss, affects p
branch point, and consequently promotes AID exon 4 skipping. Point mutations that g
antagonized the inhibitive effect of RBM5 on the splicing of intron 3 most likely due to2 and 3), but not GST control protein (Fig. 4C, lane 7), formed RNP
complexes with p5 RNA probe in vitro. Interestingly, existence of
increasing amounts of RBM5 protein (lane 3–6), but not GST
control protein (lane 8), led to a dramatic decrease of U2AF65–
RNA complex formation (Fig. 4C), indicating that RBM5 directly
competes with U2AF65 for binding to the polypyrimidine tract at
the 30-ss of intron 3 in vitro.4. Discussion
Byemployingamini-gene-based screen inHeLa cells,wedemon-
stratedhere that overexpressionofRBM5signiﬁcantlypromotesAID
exon 4 skipping by suppressing the splicing of intron 3. Theces of RNA probes containing the 30-ss of AID intron 3. Mutated nucleotides and the
e of radiolabeled probe p5, puriﬁed RBM5 protein and excessive amounts (20) of
representative photograph of the corresponding autoradiograph is shown, and the
AF65 with RNA probe p5. The radiolabeled p5 transcript was incubated with RBM5
r 0.4 pmol of recombinant RBM5 protein (lane 3–6) or 4 pmol of GST control protein
rrows and asterisks, respectively. (D) A model for RBM5 function in promoting AID
30 terminal AG dinucleotides of an intron is required for the recognition of 30-ss and
mpetes with U2AF65 for binding to the polypyrimidine tract of AID intron 3. This
respliceosome formation across exon 4, impairs the recruitment of U2 snRNP to the
enerate strong binding sites for U2AF35 at the 30-ss of AID intron 3 signiﬁcantly
stabilization of U2AF heterodimer at the 30-ss.
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U2AF35 binding site at the 30-ss. Indicative of the underlyingmech-
anism, RBM5 directly competes with U2AF65 for binding to the
polypyrimidine tract in vitro. Recruitment of U2AF heterodimer to
30-ss is a major determinant for 30-ss selection [22]. Our data thus
support a model that AID exon 4 exclusion can be modulated by
RBM5 at early stage of spliceosome assembly by competing with
U2AF65 binding at the polypyrimidine tract (Fig. 4D).
Two research groups have recently reported regulatory activities
of RBM5 in alternative splicing of two proapoptotic genes, Fas and
Caspase-2 (casp-2) [19,23]. Both studies indicate that RBM5
regulates paring of splice sites after prespliceosome assembly via
distinct mechanisms. In the case of Fas exon 6 splicing, RBM5 does
not directly interact with pre-mRNA, but affects the U4/5/6
tri-snRNP recruitmentmost likely through protein–protein interac-
tions [23]. In Caps-2 exon 9 splicing, RBM5 directly binds to a U/C-
rich RNA sequence in intron 9, similar to what was observed in AID
splicing [19]. However, the binding site of RBM5 in Casp-2 pre-
mRNA is located immediately upstream of a well-deﬁned intronic
regulatory element In100, which contains a decoy 30-ss [19]. It
has been proposed that binding of RBM5 upstream to In100 might
facilitate the formation of a pseudo-spliceosome complex between
In100 and 50-ss of intron 9. This could block spliceosome assembly
across intron 9 and consequently promote the splice sites pairing
between exon 8 and exon 10 [19]. Here we show that RBM5 is able
to interfere with the binding of U2AF65 to the 30-ss. Recruitment of
U2AF complex at the 30-ss is involved in a process termed exon def-
inition, which is required for the initiation of prespliceosome
complex formation across the spliced exon [12]. Our ﬁndings thus
support a new model whereby RBM5modulates splicing site selec-
tion by targeting molecular events that affect exon deﬁnition and
prespliceosome assembly.
A similar mechanism for regulation of exon skipping has been
reported in chicken b-Tropomyosin (b-Tm) pre-mRNA splicing
[24]. In this case, the polypyrimidine tract binding protein (PTB),
which also prefers binding to U-rich sequences within a pyrimi-
dine-rich context, represses splicing of b-Tm exon 6b by directly
interfering with the binding of U2AF65 to the polypyrimidine tract
[24]. However, while both proteins have the capacities to compete
U2AF65 binding, overexpression of PTB had only marginal effect on
AID exon 4 skipping (data not shown). These results argue that
RBM5 and PTB function through distinct molecular mechanisms
in splicing regulation, consistent with our recent ﬁndings that
RBM5, but not PTB, speciﬁcally interacts with and stimulates the
helicase activity of DHX15, a component of U2 snRNP [18].
RBM5 has long been proposed as a candidate tumor suppressor
located at cytoband 3p21.3, a chromosomal region frequently de-
leted in various cancer cells [25,26]. RBM5 can modulate expres-
sion of multiple genes controlling both apoptosis and cell
proliferation [27,28]. However, up-regulation of RBM5 is also ob-
served in some human neoplasms, suggestive of a potential pro-
moting role of RBM5 in tumor progression [29,30]. Here we show
that overexpression of RBM5 induces the expression of a putative
oncogenic isoform of AID by promoting exon 4 skipping. These
results provide insight for possible mechanism underlying a
tumor-promoting function of RBM5. It will be of interest to further
elucidate the potential pathological signiﬁcance of RBM5-
regulated alternative splicing events in future studies.
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